Introduction
============

The pancreatic β-cell plays a central role in the maintenance of glucose homeostasis by secreting insulin, a key metabolic hormone that regulates blood glucose levels. Dysfunction of the β-cell and/or a decrease in β-cell mass are associated closely with the pathogenesis and pathophysiology of diabetes mellitus, a metabolic disease that has come to afflict more than 250 million people in the world at the present time and is still increasing in prevalence globally.^[@r01])^ Studies of pancreatic β-cells provide a basis for understanding diabetes mellitus and its better treatment as well as the regulation of blood glucose levels. Current trends of pancreatic β-cell research include the mechanisms of the regulation of insulin secretion by cell signaling, the mechanisms of β-cell fate, the roles of the β-cell in the pathogenesis and pathophysiology of diabetes mellitus, and the development of novel therapies targeting the β-cell. In the past two decades, we have focused on the following issues: 1) identification of novel signaling pathways (molecules) in the regulation of insulin secretion, 2) the manner in which the intracellular signals that regulate insulin secretion are spatially and temporally integrated in β-cells, 3) the mechanism of acquisition of insulin secretory function in the process of β-cell differentiation, and 4) the relationship between abnormalities in β-cell signaling and the development of diabetes. We are also endeavoring to translate the information obtained by our basic research into clinical practice. In this review, the cell signaling critical for insulin secretory function will be discussed by describing our recent studies on the potentiation of insulin secretion by cAMP signaling and the induction of insulin secreting-cells from exocrine pancreas *in* *vitro*.

1. Potentiation of insulin secretion by cAMP signaling
======================================================

Stimulus--secretion coupling is a fundamental biological event in the β-cells.^[@r02],[@r03])^ Ca^2+^, ATP, cAMP, and phospholipid-derived signals such as inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) are the major intracellular signals in insulin secretion (Fig. [1](#fig01){ref-type="fig"} ). Glucose-stimulated insulin secretion (GSIS) is the principal mechanism of insulin secretion. According to the generally accepted model of GSIS, an increase in the ATP concentration (or ATP/ADP ratio) due to increased glucose metabolism closes the ATP-sensitive K^+^ (K~ATP~) channels, depolarizing the β-cell membrane and opening the VDCCs, which allows Ca^2+^ influx. The resultant rise in \[Ca^2+^\]~i~ in the β-cell triggers exocytosis of insulin granules. Thus, K~ATP~ channels couple metabolic changes to membrane potential.^[@r04])^ In addition to GSIS, signals involved in the potentiation of GSIS are also important for normal regulation of insulin secretion. These include cAMP, DAG, and IP3, among which cAMP is particularly important for amplifying GSIS. cAMP is now known to have diverse actions in insulin secretion. We have recently found that the cAMP sensor cAMP-GEFII (Epac2) (referred to as Epac2 hereafter)-mediated mechanism is required for the action of sulfonylureas, widely used drugs in the treatment of diabetes, as well as for the potentiation of GSIS by cAMP in a protein kinase A (PKA)-independent manner.

Modes of insulin granule exocytosis.
------------------------------------

Insulin granule exocytosis includes several steps including recruitment, docking, priming, and fusion to the plasma membrane. Recently, investigation of insulin granule exocytosis has been refined by the use of the total internal reflection fluorescence microscopy (TIRFM) system.^[@r05]--[@r07])^ We monitored the dynamics of insulin granule exocytosis from primary cultured pancreatic β-cells infected with adenovirus carrying insulin fused with yellow fluorescent protein (Venus).^[@r06])^ Analyses by TIRFM in detail revealed that the exocytotic process can be classified into three modes based on the dynamics of the granules: mode 1, in which predocked granules are immediately fused to the plasma membrane by stimulation (named *old* *face*); mode 2, in which granules are newly recruited by stimulation and immediately fused (a docking state can hardly be detected by TIRFM) to the plasma membrane (named *restless* *newcomer*); and mode 3, in which granules are newly recruited by stimulation, but are first paused or docked and then fused to the plasma membrane (named *resting* *newcomer*)^[@r06])^ (Fig. [2](#fig02){ref-type="fig"}A ). We investigated to determine whether the different modes of insulin granule exocytosis might be caused by different stimuli. Fusion events induced by potassium stimulation occur immediately upon stimulation with potassium, and are transient. The majority of these granules are *old* *face*. In contrast, fusion events induced by glucose stimulation are biphasic: a first phase of acute increase and a second phase of sustained increase. Interestingly, both phases of fusion events induced by glucose stimulation involve mostly *restless* *newcomer*. The existing model of GSIS indicates that the first phase of insulin secretion results from the fusion of insulin granules from a readily releasable pool (RRP) comprising predocked granules (*old* *face*)^[@r08])^; the second phase results from fusion of insulin granules from a reserve pool (RP) comprising granules located farther away.^[@r09])^ Our data suggest a new model of exocytosis in which both phases are caused by newly recruited granules (*restless* *newcomer*), some of which are from a distance away from the plasma membrane yet are readily releasable (Fig. [2](#fig02){ref-type="fig"}B). In fact, we found that the granule pool providing *restless* *newcomer* is likely to be located more than 50 nm from the plasma membrane.^[@r10])^

To ascertain which granule pools are involved in glucose and potassium stimulation, β-cells were sequentially treated with the secretagogues under two different protocols.^[@r10])^ In one protocol, in which the cells were stimulated with high potassium (60 mM) after glucose stimulation (16.7 mM), the fusion events occurred immediately and transiently, and were caused mainly by *old* *face*, as was found in the case of potassium stimulation alone without initial glucose stimulation. In another protocol, in which the cells were stimulated with glucose after potassium stimulation, both the first and second phases of fusion events induced by glucose stimulation were caused mostly by *restless* *newcomer*, similar to the case in which the cells were stimulated with glucose alone without initial potassium stimulation. These findings indicate that potassium stimulation and glucose stimulation induce fusion of granules from distinct pools.

Importance of cAMP signaling in insulin secretion.
--------------------------------------------------

It is well known that oral administration of glucose induces a greater insulin secretion than a comparable glucose challenge given intravenously.^[@r11],[@r12])^ This is the so-called incretin effect, which refers to the potentiating action of gastrointestinal hormones on insulin secretion, including GLP-1 (Glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide, originally called gastric inhibitory polypeptide).^[@r13],[@r14])^ GLP-1 and GIP are released in response to the ingestion of nutrients from gastrointestinal endocrine L-cells and K-cells, respectively.^[@r15])^ Both of these hormones potentiate GSIS^[@r16])^ by activation of cAMP signaling in pancreatic β-cells.^[@r17]--[@r19])^ cAMP acts on insulin secretion at various steps.^[@r20]--[@r22])^ In normal pancreatic islets, *in* *vitro* concentration-dependency of GSIS displays a sigmoidal curve^[@r23])^ in which a glucose concentration exceeding 6 mmol/l is required for triggering insulin secretion. On the other hand, a study in man showed that GLP-1 infusion induced a significant increase in insulin secretion even at fasting glucose levels of around 5.1 mmol/l.^[@r24])^ In addition, it has been reported that GLP-1 endows glucose-insensitive β-cells with glucose-competency, probably by modulating K~ATP~ channel activity.^[@r25])^ These findings suggest a mechanism by which cAMP may induce glucose responsiveness of pancreatic β-cells. We recently found that treatment with GLP-1 induced glucose responsiveness in K~ATP~ channel-deficient (Kir6.2 null) mice in which there was almost no insulin secretion in response to glucose,^[@r22])^ indicating that activation of cAMP signaling is important for induction of glucose responsiveness in K~ATP~ channel-deficient β-cells and that GLP-1 induces GSIS by the K~ATP~ channel-independent mechanism.

GSIS is usually assessed by the insulin response to a rapid and large increase in glucose concentration, *e.g.*, from 2.8 mM to 16. 7 mM *in* *vitro*. However, such drastic change in glucose concentration is unlikely to occur *in* *vivo*, in which blood glucose levels gradually increase within a narrow range when glucose is taken orally. To confirm the importance of cAMP signaling in GSIS under physiological conditions, we increased the glucose concentration in a stepwise manner in the presence or absence of cAMP in perfused pancreas. Interestingly, these small and stepwise increases in glucose concentration from 2.8 mM to 11 mM failed to trigger insulin secretion in the absence of 8-Bromo-cAMP or GLP-1, but dramatically evoked insulin secretion in its presence. Such GSIS was almost completely abolished by treatment with niflumic acid. Considering that the blood glucose concentrations increase gradually after meal ingestion from 4--5 mmol/l to less than 8.0 mmol/l^[@r26])^ with concomitant rises in incretin levels, pancreatic β-cell cAMP signaling activated by incretins may well play an important role in maintaining the blood glucose level within the physiological range. Thus, niflumic-sensitive channels seem to be critically involved in the mechanism of induction of GSIS by cAMP in the physiological state.^[@r22])^

Role of Epac2 (cAMP-GEFII)/Rap1 signaling in insulin secretion.
---------------------------------------------------------------

cAMP is a universal intracellular second messenger involved in regulation of various cellular functions in many cell types. It has long been thought that cAMP regulates the potentiation of insulin secretion through PKA phosphorylation of various proteins associated with the insulin secretory process.^[@r02],[@r27]--[@r29])^ However, it is now known that cAMP potentiates insulin granule exocytosis by PKA-independent as well as PKA-dependent mechanisms, the former involving the cAMP-binding protein Epac2.^[@r30]--[@r32])^ Epacs, Epac1 (also known as cAMP-GEFI) and Epac2 (cAMP-GEFII), have so far been identified.^[@r33]--[@r35])^ Recently, a novel variant Epac2 lacking the N-terminal cAMP-binding domain of the known Epac2 was found in mouse adrenal glands and designated Epac2B (*i.e.* adrenal type); Epac2 is now called Epac2A (brain/β-cell type).^[@r36])^ A previously identified variant, which is specifically expressed in liver, is referred to as Epac2C (liver type).^[@r37])^ Both Epac1 and Epac2 proteins possess guanine nucleotide exchange activity towards the small G-proteins Rap1 and Rap2 in a cAMP-dependent manner.^[@r33]--[@r35])^ Structurally, both Epac proteins have common features: a cAMP-binding domain and DEP (Dishevelled, Egl-10, and Pleckstrin), REM (Ras exchange motif), and GEF (guanine nucleotide exchange factor) domains. Epac1 possesses one cAMP-binding domain while Epac2 possesses two cAMP-binding domains. Binding of cAMP to Epac2 is thought to cause conformational changes that elicit GEF activity toward Rap proteins.^[@r38])^

We previously showed that Epac2 mediates the potentiation of cAMP-dependent, PKA-independent insulin secretion.^[@r27],[@r31],[@r39])^ To clarify the role of Epac2 in insulin granule exocytosis directly, we examined exocytosis in pancreatic β-cells isolated from Epac2-deficient (Epac2 null) mice using the TIRFM system.^[@r06])^ Although there was no difference in glucose-induced exocytosis of insulin granules, we found that potentiation by cAMP of the first phase of glucose-induced exocytosis was significantly impaired in Epac2 null mice.^[@r06])^ In addition, Rap1, which is activated by cAMP specifically through Epac2 in pancreatic β-cells, was found to be required for PKA-independent cAMP-potentiated insulin secretion. Thus, Epac2/Rap1 signaling is important for the potentiation by cAMP of the first phase of GSIS. We therefore propose that Epac2/Rap1 signaling regulates cAMP-induced insulin granule exocytosis by controlling the size of the RRP, most likely through regulation of granule density^[@r06],[@r10])^ (Fig. [3](#fig03){ref-type="fig"} ).

Epac2 as a novel target of antidiabetic sulfonylurea drugs.
-----------------------------------------------------------

K^+^ channels regulated by intracellular ATP concentrations were first reported in guinea pig and rabbit cardiac cell membranes^[@r40])^ and were later found in many cell types, including pancreatic islet cells.^[@r04])^ K~ATP~ channels are critical in the regulation of GSIS by coupling ATP, produced by the metabolism of glucose, to electrical activity of the β-cell membrane, leading to calcium influx through opening of VDCCs. It was found that tolbutamide, an antidiabetic drug, inhibits K~ATP~ channels in pancreatic β-cells, which suggested that the channels are the target of sulfonylureas (SUs).^[@r41])^ In 1995, the sulfonylurea receptor (now called SUR1) from pancreatic β-cell cDNA libraries was cloned by Aguilar-Bryan *et* *al.*^[@r42])^ SUR1 is a member of the ATP-binding cassette (ABC) protein superfamily. We cloned Kir6.2,^[@r43])^ a member of the inwardly rectifying K^+^ channel family, and established that the β-cell K~ATP~ channel is composed of Kir6.2 and SUR1,^[@r43])^ which provided a basis of understanding of K~ATP~ channels. Kir6.1 was cloned prior to Kir6.2.^[@r44])^ The K~ATP~ channel is a hetero-octameric complex comprising two subunits: a pore-forming subunit Kir6.x (Kir6.1 or Kir6.2) and a regulatory subunit SURx (SUR1, SUR2A, or SUR2B).^[@r45],[@r46])^ Different combinations of Kir6.1 or Kir6.2 and SUR1 or SUR2 variant (mix and match) form K~ATP~ channels with differing nucleotide and SU sensitivities that play distinct physiological and pathophysiological roles in different tissues.^[@r47])^ While Kir6.2 plus SUR1 constitutes pancreatic β-cell K~ATP~ channels, Kir6.2 plus SUR2A constitutes cardiac and skeletal muscle K~ATP~ channels. Kir6.2 plus SUR2B constitutes smooth muscle K~ATP~ channels and Kir6.1 plus SUR2B constitutes vascular smooth muscle K~ATP~ channels, both of which are somewhat ATP-insensitive, nucleotide diphosphate-activated, and glibenclamide-sensitive K^+^ channels. It is now known that mutations of K~ATP~ channels cause persistent hyperinsulinemic hypoglycemia of infancy and neonatal diabetes, depending on loss-of-function mutation or gain-of-function mutation.^[@r48])^ K~ATP~ channels, as metabolic sensors, play critical roles in various functions such as insulin secretion, glucagon secretion,^[@r49])^ and protection against hypoxia-induced seizure^[@r50])^ and ischemic heart.^[@r51])^

Mice lacking K~ATP~ channels (Kir6.2 null mice and SUR1 null mice) were generated.^[@r52],[@r53])^ Neither glucose nor tolbutamide stimulation elicited any change in \[Ca^2+^\]~i~ in Kir6.2 null β-cells.^[@r52])^ Importantly, neither glucose nor tolbutamide stimulation caused a significant insulin secretion in Kir6.2 null mice. The study of SUR1 null mice confirmed also that both glucose-induced and sulfonylurea-induced insulin secretion depend critically on the activity of β-cell K~ATP~ channels.^[@r53])^ Based on these findings, it is generally accepted that the primary target of SUs is SUR1 and that action of SUs is mediated by closure of the K~ATP~ channels through binding to SUR1.

In the course of our study of the Epac2-mediated mechanisms of insulin secretion, we developed a fluorescence resonance energy transfer (FRET)-based Epac2 sensor (termed C-Epac2-Y) in which the full-length Epac2 is fused amino-terminally to enhanced cyan fluorescent protein (ECFP) and carboxyl-terminally to enhanced yellow fluorescent protein (EYFP).^[@r54])^ Epac2 is a closed form in the inactive state,^[@r32])^ so that ECFP and EYFP are located very closely to each other (within 10 nm), which causes FRET. Upon cAMP binding to Epac2, Epac2 changes its conformation to an open form. As a result, ECFP and EYFP separate away, so that FRET does not occur (active state). Utilizing this principle, we are able to monitor the activation status of Epac2. In the search for agents that activate Epac2 using this FRET sensor, we found that tolbutamide, glibenclamide, chlorpropamide, acetohexamide, and glipizide significantly decrease the FRET response in COS-1 cells transfected with Epac2 FRET sensor, in different degrees and varying kinetics, suggesting strongly that these SUs activate Epac2. However, gliclazide, another SU, does not decrease the FRET response. These findings indicate that the core structure of sulfonylurea is required for binding to Epac2. The fact that gliclazide, a sulfonylurea having a side chain on the urea group larger than that of other sulfonylureas, does not decrease FRET suggests that the structure or size (or both) of the side chain on the urea group determines the capability of interaction between sulfonylureas and Epac2. Direct binding of SU to Epac2 was confirmed by specific binding of radiolabeled glibenclamide to Epac2 expressed in COS-1 cells. Binding of \[^3^H\]glibenclamide to Epac2 was inhibited by unlabeled tolbutamide or unlabeled glibenclamide in a concentration-dependent manner, indicating that tolbutamide binds specifically to Epac2 at the same binding site as glibenclamide does. Specific binding of glibenclamide to Epac2 was not significantly inhibited in the presence of 8-Bromo-cAMP, suggesting that the sulfonylurea-binding site is distinct from the cAMP-binding sites.

We also found that tolbutamide and glibenclamide activate Rap1 in clonal pancreatic β-cells (MIN6 cells), but gliclazide does not. Interestingly, although there was no difference in GSIS between wild-type mice and Epac2 null mice, tolbutamide-induced insulin secretion and glibenclamide-induced insulin secretion from isolated pancreatic islets of Epac2 null mice were significantly reduced, compared to those of wild-type mice. However, there was no significant difference in insulin secretion in response to gliclazide between wild-type mice and Epac2 null mice. Furthermore, the insulin response to oral administration of tolbutamide alone or concomitant administration of glucose and tolbutamide in Epac2 null mice was significantly reduced, compared to that in wild-type mice, and the glucose lowering effect of tolbutamide in Epac2 null mice was significantly less than that in wild-type mice.

As described above, it is well established that SUs stimulate insulin secretion by eliciting a series of ionic events including closure of K~ATP~ channels, opening of VDCCs, and Ca^2+^ influx into the β-cells. Although closure of the K~ATP~ channels is prerequisite for SUs to stimulate insulin secretion, activation of Epac2/Rap1 signaling is required for SUs to exert their full effects in insulin secretion. Considering the role of Epac2/Rap1 signaling in insulin granule exocytosis described above, SUs may well increase the size of a RRP of insulin granules near the plasma membrane (Fig. [4](#fig04){ref-type="fig"} ).

2. Induction of insulin secreting-cells from pancreatic exocrine cells *in* *vitro*
===================================================================================

Although it has been reported that embryonic stem (ES) cells can be manipulated to produce insulin,^[@r55]--[@r58])^ there are several obstacles to their clinical use. Transplantation of ES cell derivatives into human recipients can result in formation of ES cell-derived tumors.^[@r59])^ Ethical problems also arise in the acquisition of human ES cells.^[@r60])^ In addition, it has been suggested that both the production and the release of insulin in such manipulated ES cells may be abnormal.^[@r61],[@r62])^ On the other hand, recent studies have shown that insulin-secreting cells can be generated *in* *vitro* from adult non-β-cells including mouse and human pancreatic duct cells,^[@r62]--[@r65])^ rat hepatic oval cells,^[@r66])^ and mouse bone marrow cells.^[@r67])^ Although it was thought that terminally differentiated cells do not change their phenotype, accumulating evidence suggests that phenotypic plasticity is retained in differentiated cells. The most intriguing example is induced-pluripotent stem (iPS) cells, which have ES-cell like properties, generated from somatic cells by introducing defined factors.^[@r68])^ Insulin-secreting cells have been generated from such iPS cells.^[@r69])^ However, the use of iPS cells retains problems similar to those involved in the use of ES cells except for the ethical issues. On the other hand, it has been shown that adult cells occasionally change their phenotype without reprogramming into ES-like pluripotent cells in chronic damage and tissue regeneration, a phenomenon often called transdiffrenation.^[@r70])^ The pancreas is an organ in which metaplasia, a pathological state involving transdifferentiation,^[@r71],[@r72])^ frequently occurs. For example, hepatocyte-like cells appear in human pancreatic cancer in some cases,^[@r73])^ and experimental conditions such as copper depletion can lead to the development of pancreatic hepatocytes in rodents.^[@r74],[@r75])^ Since a large number of pancreatic exocrine cells can be obtained as a byproduct of islet transplantation, the exocrine pancreas is a potential source for the generation of transplantable surrogate β-cells. *In* *vitro* generation of insulin-positive cells from pancreatic exocrine cells has been reported by several groups.^[@r76],[@r77])^ However, neither direct evidence of the origin of these cells nor their precise insulin secretory properties was shown in those studies.

Generation of insulin-positive cells from pancreatic exocrine cells.
--------------------------------------------------------------------

We have established a method for the generation of insulin-secreting cells from pancreatic exocrine cells in mice.^[@r78])^ The pancreatic exocrine cell-enriched fraction was prepared by Ficoll density gradient centrifugation. By this method, pancreatic exocrine cells are recovered as a pellet, and are then stained with dithizone, a zinc-chelating agent, to remove contaminated pre-existing pancreatic β-cells. The resulting fraction contains \>90% of amylase-positive cells, approximately 5% of cytokeratin-positive cells, and less than 0.01% of insulin-positive cells. The exocrine cell-enriched fractions were then cultured in RPMI-1640 medium supplemented with 0.5% fetal calf serum (FCS) and 20 ng/ml of EGF. Under these conditions, the cells readily formed aggregates and became smooth spheroids within a few days (Fig. [5](#fig05){ref-type="fig"} ). We found that a subset of the cells in these colonies expressed insulin. Most insulin-positive cells were detected at the peripheral of small colonies. When the isolated pancreatic exocrine cells were cultured in suspension using dishes treated with 2-methacryloyloxyethyl phosphorylcholine (MPC), which interferes with cell attachment, insulin production was increased compared to that in monolayer culture. The frequency of insulin-positive cells was increased to ∼5% of total cells on day 4. The insulin-positive cells also expressed C-peptide, indicating *de* *novo* biosynthesis of insulin in these cells. Both amylase and elastase, which are acinar cell-specific enzymes, were strongly detected before culture (day 0) at both mRNA (RT-PCR) and protein (immunoblotting) levels. Immunocytochemistry showed that both amylase- and elastase-positive cells comprised more than 90% of total cells in the initial preparation (day 0), but less than 5% 4 days after culture. While CK (ductal marker)-positive cells were rare at day 0, CK-positive ductal structures were found frequently at day 4 and day 6. Although insulin-positive cells were generally negative for amylase, a few cells clearly expressed both insulin and amylase, suggesting that the insulin-producing cells in the culture are derived from amylase/elastase-expressing mature pancreatic acinar cells.^[@r78])^

Origin of the newly made insulin-positive cells.
------------------------------------------------

To identify the origin of the newly-made insulin-producing cells, we utilized the method of cell lineage tracing. In this method, ROSA26-loxP-stop-loxP-ECFP reporter mouse (R26R-ECFP)-expressing ECFP that can be activated through the action of Cre recombinase^[@r79])^ and adenoviruses in which either amylase-2 (Ad-pAmy-Cre) or elastase-1 (Ad-pEla-Cre) promoter that drives the expression of Cre recombinase are used. Pancreatic exocrine cells from R26R-ECFP mice were infected with these adenoviruses to label pancreatic acinar cells, and cultured as described. After the culture, ECFP-expressing insulin-positive cells were frequently found, demonstrating that the insulin-positive cells originate from amylase-expressing pancreatic acinar cells.^[@r78])^ We also found that glucagon-positive cells, somatostatin-positive cells, and a subset of CK-positive cells in the culture also originate from the acinar cells.^[@r80])^ Accordingly, pancreatic acinar cells possess plasticity to convert into both endocrine and ductal cells.

Properties of the newly made cells.
-----------------------------------

Glucose transporters, glucokinase, K~ATP~ channels, VDCCs, molecules associated with the exocytotic machinery (SNAREs), and prohormone convertases (PC1/3 and PC2) are required for proper GSIS. The expressions of all of these molecules were induced or up-regulated in pancreatic acinar cells after the culture. The expression profiles of the exocrine pancreas-derived insulin-producing cells became similar to those of pancreatic islets. In addition, formation of insulin-containing granules was confirmed by immunoelectron microscopy, indicating that these cells can secrete insulin in a regulated manner. Indeed, KCl at a high concentration stimulated insulin secretion from the pancreatic acinar-derived cells, indicating the occurrence of Ca^2+^-triggered exocytosis. Insulin secretion also was increased by glibenclamide, a sulfonylurea commonly used in treatment of diabetes, indicating that functional K~ATP~ channels are expressed. Importantly, GSIS from exocrine pancreas-derived cells was detected in a concentration-dependent manner, indicating that the cells are glucose responsive. In addition, GLP-1 (7-36 amide), an incretin, potentiated insulin secretion in the presence of relatively high concentrations of glucose, indicating that the cAMP-mediated potentiation system also is present in the cells (Fig. [6](#fig06){ref-type="fig"} ). These results show that pancreatic acinar-derived cells have qualitatively similar insulin secretory properties to those of native pancreatic β-cells. However, insulin content in these pancreatic acinar-derived cells (including both insulin-positive and insulin-negative cells) is only 1/400 that of native pancreatic islets. Since the frequency of insulin-positive cells is approximately 5% of total cells in the culture, the insulin content of the newly made insulin-positive cells is about 1/20 that of a native β-cell^[@r78])^ on a cell to cell basis.

Dedifferentiation and redifferentiation processes in induction of the insulin-secreting cells.
----------------------------------------------------------------------------------------------

During development of the pancreas, several transcription factors are known to play critical roles in β-cell differentiation. Pdx1, a transcription factor seen early in the developing pancreas and restricted to β-cells in adults, was induced in pancreatic acinar-derived cells by the culture at both mRNA and protein levels. Other transcription factors characteristic of endocrine pancreas (NeuroD1, Isl1, Pax6, Nkx2.2, Nkx6.1, Hlxb9, HNF1a, and Foxa1) also were induced. Foxa2 is expressed in early endoderm^[@r81])^ and all pancreatic cell types including endocrine and exocrine cells in adult.^[@r82])^ Although we could not detect Foxa2 expression in isolated acinar cells, probably due to the low expression level, Foxa2 was induced at both mRNA and protein levels after the culture. HNF6, which is required for the expression of Foxa2,^[@r83])^ also was induced. Ptf1a expression was increased by the culture. Although Ptf1a was thought to be an exocrine-specific transcription factor,^[@r84])^ a recent study has shown that this factor also is expressed in the pancreatic bud and is required for differentiation into all three cell types (endocrine, exocrine, and duct) of the pancreas.^[@r85])^ These results suggest that pancreatic acinar cells dedifferentiate into cells having the properties of endocrine progenitors.

Cell signaling required for induction of insulin-secreting cells from pancreatic acinar cells *in* *vitro*.
-----------------------------------------------------------------------------------------------------------

We found that enzymatic dissociation of the pancreas leads to activation of the EGF receptor and its downstream signaling. The EGF receptor was not activated before dissociation but was activated (tyrosine phosphrylated) by enzymatic dissociation. When an inhibitor of EGF receptor kinase (AG1478) was applied, transdifferentiation of isolated pancreatic acinar cells into insulin-secreting cells was inhibited,^[@r78])^ demonstrating that activation of the EGF receptor is essential for the transdifferentiation. In embryonic pancreas, EGF increases the number of undifferentiated endocrine precursor cells, and, upon removal of EGF, a large number of β-cells are differentiated,^[@r86])^ suggesting that EGF may be important for the proliferation of endocrine precursors and/or endow the cells with commitment to endocrine lineage. We have found that activation of the PI3-kinase pathway is critical for the transdifferentiation of pancreatic acinar cells into insulin-secreting cells and have shown that isolated pancreatic acinar cells form spheroids (3-D structures) when cultured in the presence of EGF.^[@r87])^ In the presence of a PI3-kinase inhibitor, LY294002, the formation of spheroids was blocked and induction of the genes characteristic of pancreatic β-cells was significantly suppressed, demonstrating that PI3-kinase is essential for the transdifferentiation of pancreatic acinar cells into insulin-secreting cells. These results suggest that cell--cell interaction is involved in the process. Although cadherin-mediated cell--cell adhesions were disrupted by enzymatic dissociation of pancreatic acinar cells, they were recovered by culture with EGF. Since cell-to-cell contact is known to play important roles in fate determination of many cell types, the impacts of inhibition of cell-to-cell contact on such transdifferentiation were investigated using a neutralizing antibody against E-cadherin (ECCD-1). When spheroid formation in isolated acinar cells was inhibited by addition of the antibody, inductions of genes specific for pancreatic β-cells were significantly suppressed, while transcription factors seen early in pancreas development such as HNF6 and Foxa2 were still up-regulated^[@r87])^ (Fig. [7](#fig07){ref-type="fig"} ). Activation of PI3-kinase resulted in up-regulation of both E-cadeherin and β-catenin, major components of cadherin-mediated cell--cell adhesion, and blocked degradation of these proteins, which leads to the recovery of the adhesion. It has been reported that acinar-to-β cell transdifferentiation is not found *in* *vivo*.^[@r88])^ This is probably because loss of cell adhesion of pancreatic acini rarely occurs *in* *vivo*.

Model of the mechanism of induction of insulin-secreting cells from pancreatic acinar cells *in* *vitro*.
---------------------------------------------------------------------------------------------------------

A model of pancreatic acinar-to-β cell transdifferentiation is depicted in Fig. [8](#fig08){ref-type="fig"} : enzymatic dissociation of exocrine pancreas disrupts the epithelial structures of acini, including cadherin-mediated cell--cell adhesion, which causes dedifferentiation of the acinar cells. Spontaneous activation of the EGF receptor and its downstream signals occurs after isolation of the cells, and the addition of EGF enhances these signals. Remodeling of cell--cell interaction by restored cadherin-mediated cell--cell adhesion, which is promoted by activation of the PI3-kinase pathway, induces redifferentiation of the dedifferentiated pancreatic acinar cells into insulin-secreting cells. Thus, loss and restoration of PI3-kinase-dependent cadherin-mediated cell--cell adhesion is essential for induction of insulin-secreting cells from pancreatic acinar cells *in* *vitro*.

Coda
====

Although the discovery of insulin in 1921 by Banting and Best brought the first and foremost good news to patients with diabetes mellitus, how the pancreatic β-cell produces and secretes insulin and how the β-cell is generated and maintained are still puzzling questions. Normal pancreatic β-cells are equipped with a very precise apparatus that allows adjustment of insulin secretion in response to moment-to-moment changes in blood glucose levels, and thus precisely maintain blood glucose levels within the narrow physiological range that protects the various organs from the development of the many serious diabetic complications. In addition to insulin, various antidiabetic drugs targeting β-cells have been developed to treat diabetes. Understanding the signaling mechanisms of insulin secretion and those of the generation of β-cells should provide clues for development of novel therapeutic strategies as well as understanding the signaling mechanisms of insulin secretion and those of the generation of β-cells should provide clues for development of novel therapeutic strategies as well as clarification of the pathogenesis and pathophysiology of diabetes.
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![GSIS and its potentiation. Glucose is transported into the pancreatic β-cell by the glucose transporter (GLUT). Metabolism of glucose increases ATP production, closing the K~ATP~ channels, which results in membrane depolarization (Δψ), thus opening of voltage-dependent calcium channels (VDCC) and allowing Ca^2+^ influx. The resultant rise in \[Ca^2+^\]~i~ triggers insulin secretion. Insulin secretion is also modulated by hormones and neurotransmitters. Incretins such as GLP-1 and GIP bind to Gs-coupled receptors and activate adenylyl cyclase (AC), which increases intracellular levels of cyclic AMP. cAMP activates both PKA and Epac2 to potentiate insulin secretion. Achetylcholine (ACh), a major parasympathetic neurotransmitter, binds to Gq-coupled receptors and activates phospholipase Cβ (PLCβ). PLCβ activation generates phospholipid-derived messengers. Among these, DAG activates PKC and IP3 mobilizes Ca^2+^ from intracellular storage sites.](pjab-86-563-g001){#fig01}

![A. Modes of insulin granule exocytosis. There are three modes of insulin granule exocytosis, based on the dynamics of the granules. *Old* *face*: predocked granules that are fused to the plasma membrane by stimulation. *Restless* *newcomer*: granules that are newly recruited by stimulation and immediately fused to the plasma membrane. *Resting* *newcomer*: granules that are newly recruited by stimulation, docked, and fused to the plasma membrane by stimulation. Sequential images (1 µm × 1 µm) acquired every 300 msec show these different dynamics; the flash indicates the fusion events. B. Models of GSIS. In the existing model of GSIS (Ref. [@r08]), the first phase results from a readily releasable pool (RRP) comprising docked insulin granules ("*old* *face*" as defined); the second phase results from a reserve pool (RP) comprising granules located farther away ("*resting* *newcomer*" as defined). In the new model, a RRP responsible for the first phase is located more than 50 nm from the plasma membrane but is yet immediately releasable, and both the first and second phases of GSIS comprise *restless* *newcomer*. Blue, orange, and red indicates insulin granule exocytosis comprising *old* *face*, *resting* *newcomer*, and *restless* *newcomer*, respectively.](pjab-86-563-g002){#fig02}

![Potentiation of insulin secretion by Epac2/Rap1 signaling. Activation of Epac2/Rap1 signaling promotes cAMP-induced, PKA-independent insulin granule exocytosis by increasing the size of a readily releasable pool (RPP) near the plasma membrane. Epac2 includes cAMP-binding domain A and cAMP-binding domain B, DEP domain, REM, RA domain, and GEF.](pjab-86-563-g003){#fig03}

![Model of sulfonylurea stimulation of insulin secretion. SUs close K~ATP~ channels by binding to SUR1, which leads to calcium influx by opening of VDCCs. SUs also bind Epac2 to activate Rap1 signaling, which increases the size of a RRP of insulin granules near the plasma membrane.](pjab-86-563-g004){#fig04}

![Spheroids formed by pancreatic acinar cell culture. A. The pancreatic acinar cells form spherical cell clusters within a few days by culture with EGF. B. Insulin-positive cells are shown in culture.](pjab-86-563-g005){#fig05}

![Insulin secretion from transdifferentiated pancreatic acinar cells. Insulin secretion is stimulated by glucose and enhanced by glucagon-like peptide-1 (GLP-1) (7--36 amide) (100 nM).](pjab-86-563-g006){#fig06}

![Dedifferentiated state in pancreatic acinar cells. Gene expression profiling of isolated pancreatic acinar cells cultured in the presence of LY294002 and nicotinamide was performed. Quantification of changes in gene expression is shown. The mRNA expression level of each gene on day 0 was considered as 1. \**P* \< 0.05; \*\**P* \< 0.01, unpaired *t*-test.](pjab-86-563-g007){#fig07}

![Model for pancreatic acinar-to-β cell transdifferentiation. Enzymatic dissociation disrupts epithelial structures of acini, resulting in loss of cadherin-mediated cell--cell adhesion, which causes dedifferentiation of the acinar cells. Meanwhile, EGF receptors are activated, which is followed by activation of the PI3-kinase pathway. Within a few days of culture, cadherin-mediated cell--cell adhesion is recovered by the enhanced expression of E-cadherin, which is essential for redifferentiation of the dedifferentiated cells into insulin-secreting cells.](pjab-86-563-g008){#fig08}
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